Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01914484
What this trial is testing

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Who this might be right for
Chronic Phase Chronic Myeloid LeukemiaAccelerated Phase Chronic Myeloid LeukemiaBlastic Phase Chronic Myeloid Leukemia+2 more
University Health Network, Toronto 4
Testing effectiveness (Phase 2)Study completedNCT02713386
What this trial is testing

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous Adenocarcinoma+23 more
NRG Oncology 147
Testing effectiveness (Phase 2)UnknownNCT03613428
What this trial is testing

Ruxolitinib Plus LVP in Patients With R/R ETP-ALL

Who this might be right for
Acute T Cell Leukemia
Sichuan University 12
Testing effectiveness (Phase 2)Ended earlyNCT03878199
What this trial is testing

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Who this might be right for
Essential ThrombocythemiaMyelofibrosisMyeloproliferative Neoplasm+2 more
Ohio State University Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT01348490
What this trial is testing

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 66
Early research (Phase 1)Active Not RecruitingNCT07576010
What this trial is testing

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Who this might be right for
Acute Graft-versus-host Disease
Daihong Liu 30
Early research (Phase 1)Looking for participantsNCT05714072
What this trial is testing

Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Who this might be right for
Myelofibrosis Due to and Following Polycythemia Vera
Memorial Sloan Kettering Cancer Center 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT06399029
What this trial is testing

Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities

Who this might be right for
ExanthemaLichenoid Skin Rashes Under Anti-PD1 Tumor Therapy
University of Zurich 22
Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Testing effectiveness (Phase 2)Ended earlyNCT04543279
What this trial is testing

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Who this might be right for
MyelofibrosisThrombocytopenia
Washington University School of Medicine 3
Not applicableApproved For MarketingNCT05722912
What this trial is testing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Who this might be right for
Graft-versus-host Disease (GVHD)
Incyte Corporation
Early research (Phase 1)Study completedNCT03920852
What this trial is testing

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 41
Testing effectiveness (Phase 2)Study completedNCT04334044
What this trial is testing

Treatment of SARS Caused by COVID-19 With Ruxolitinib

Who this might be right for
COVID-19Severe Acute Respiratory Syndrome Coronavirus 2
Grupo Cooperativo de Hemopatías Malignas 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT07725432
What this trial is testing

Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation

Who this might be right for
Immune-related Vitiligo-like-Depigmentation
University of Zurich 34
Early research (Phase 1)Ended earlyNCT06695507
What this trial is testing

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

Who this might be right for
Chronic Graft Versus Host Disease
Children's Hospital Medical Center, Cincinnati 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197112
What this trial is testing

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

Who this might be right for
Acute Graft Versus Host Disease Grade II-IVAcute Graft vs Host Disease
Ruijin Hospital 15
Large-scale testing (Phase 3)Study completedNCT03745651
What this trial is testing

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Who this might be right for
Atopic Dermatitis
Incyte Corporation 618
Testing effectiveness (Phase 2)Looking for participantsNCT05817955
What this trial is testing

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

Who this might be right for
MDS/MPN
The First Affiliated Hospital with Nanjing Medical University 50
Testing effectiveness (Phase 2)Ended earlyNCT06397313
What this trial is testing

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis
Ryvu Therapeutics SA 36
Testing effectiveness (Phase 2)Study completedNCT04281498
What this trial is testing

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Who this might be right for
Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
John Mascarenhas 6
Next Page